JP2023521163A - Ｓａｒｓ－ｃｏｖ－２感染症を治療する方法 - Google Patents

Ｓａｒｓ－ｃｏｖ－２感染症を治療する方法 Download PDF

Info

Publication number
JP2023521163A
JP2023521163A JP2022561997A JP2022561997A JP2023521163A JP 2023521163 A JP2023521163 A JP 2023521163A JP 2022561997 A JP2022561997 A JP 2022561997A JP 2022561997 A JP2022561997 A JP 2022561997A JP 2023521163 A JP2023521163 A JP 2023521163A
Authority
JP
Japan
Prior art keywords
dantrolene
administering
subject
pharmaceutically acceptable
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521163A5 (https=
Inventor
ヘプナー、エイドリアン
Original Assignee
イーグル ファーマスーティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーグル ファーマスーティカルズ、インク． filed Critical イーグル ファーマスーティカルズ、インク．
Publication of JP2023521163A publication Critical patent/JP2023521163A/ja
Publication of JP2023521163A5 publication Critical patent/JP2023521163A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022561997A 2020-04-10 2021-04-08 Ｓａｒｓ－ｃｏｖ－２感染症を治療する方法 Pending JP2023521163A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008486P 2020-04-10 2020-04-10
US63/008,486 2020-04-10
US202063062599P 2020-08-07 2020-08-07
US63/062,599 2020-08-07
PCT/US2021/026302 WO2021207443A1 (en) 2020-04-10 2021-04-08 Methods of treating sars-cov-2 infections

Publications (2)

Publication Number Publication Date
JP2023521163A true JP2023521163A (ja) 2023-05-23
JP2023521163A5 JP2023521163A5 (https=) 2024-04-11

Family

ID=75787221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561997A Pending JP2023521163A (ja) 2020-04-10 2021-04-08 Ｓａｒｓ－ｃｏｖ－２感染症を治療する方法

Country Status (12)

Country Link
US (1) US12605364B2 (https=)
EP (1) EP4132518B1 (https=)
JP (1) JP2023521163A (https=)
KR (1) KR20230002371A (https=)
CN (1) CN115361947A (https=)
AU (1) AU2021253866A1 (https=)
BR (1) BR112022020193A2 (https=)
CA (1) CA3174710A1 (https=)
IL (1) IL296517A (https=)
MX (1) MX2022012705A (https=)
WO (1) WO2021207443A1 (https=)
ZA (1) ZA202210474B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521162A (ja) * 2020-04-10 2023-05-23 イーグル ファーマスーティカルズ、インク． 重症急性呼吸器症候群を治療する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079721A1 (en) * 2017-10-20 2019-04-25 Eagle Pharmaceuticals, Inc. DANTROLENE PRODRUGS AND METHODS OF USE
WO2020112932A1 (en) * 2018-11-27 2020-06-04 Eagle Pharmaceuticals, Inc. Use of dantrolene and dantrolene prodrugs to treat radiation exposure
JP2023521162A (ja) * 2020-04-10 2023-05-23 イーグル ファーマスーティカルズ、インク． 重症急性呼吸器症候群を治療する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079721A1 (en) * 2017-10-20 2019-04-25 Eagle Pharmaceuticals, Inc. DANTROLENE PRODRUGS AND METHODS OF USE
WO2020112932A1 (en) * 2018-11-27 2020-06-04 Eagle Pharmaceuticals, Inc. Use of dantrolene and dantrolene prodrugs to treat radiation exposure
JP2023521162A (ja) * 2020-04-10 2023-05-23 イーグル ファーマスーティカルズ、インク． 重症急性呼吸器症候群を治療する方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANAESTHESIA, vol. 59, JPN6025013154, 2004, pages 364 - 373, ISSN: 0005722552 *
BIORXIV, JPN6025013153, 2019, pages 1 - 38, ISSN: 0005722551 *
BRAIN, BEHAVIOR, AND IMMUNITY, vol. 88, JPN6025013156, 18 May 2020 (2020-05-18), pages 28 - 29, ISSN: 0005722554 *
CHEMRXIV, JPN6025013157, 2020, pages 1 - 28, ISSN: 0005722555 *
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol. 24, JPN6025013155, October 2020 (2020-10-01), pages 10228 - 10238, ISSN: 0005722553 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521162A (ja) * 2020-04-10 2023-05-23 イーグル ファーマスーティカルズ、インク． 重症急性呼吸器症候群を治療する方法

Also Published As

Publication number Publication date
CN115361947A (zh) 2022-11-18
KR20230002371A (ko) 2023-01-05
US20230144719A1 (en) 2023-05-11
ZA202210474B (en) 2025-12-17
MX2022012705A (es) 2022-11-07
WO2021207443A1 (en) 2021-10-14
AU2021253866A1 (en) 2022-10-20
EP4132518A1 (en) 2023-02-15
IL296517A (en) 2022-11-01
US12605364B2 (en) 2026-04-21
EP4132518C0 (en) 2025-08-13
CA3174710A1 (en) 2021-10-14
BR112022020193A2 (pt) 2022-11-22
EP4132518B1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
Van Brummelen et al. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19–a formulator’s perspective
KR102233826B1 (ko) 바이러스 감염을 치료하기 위한 티아졸리드 화합물
WO2021155777A1 (zh) 药物组合物在预防和治疗新型冠状病毒肺炎中的应用
JP2023521163A (ja) Ｓａｒｓ－ｃｏｖ－２感染症を治療する方法
JP2023521162A (ja) 重症急性呼吸器症候群を治療する方法
US20230181509A1 (en) The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease
WO2021188787A1 (en) Method for treatment of coronavirus infection
KR20230021009A (ko) 항바이러스 치료로서의 아젤라스틴
HK40083259A (en) Dantrolene for use in methods of treating sars-cov-2 infections
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
US20230143775A1 (en) Methods of treating coronavirus infections
US20230149364A1 (en) Methods of treating viral infections
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
RU2794315C1 (ru) Способ профилактики или лечения коронавирусной и других острых респираторных вирусных инфекций
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
JP2025172919A (ja) 潜在的な呼吸器ウイルス感染個体にインターフェロンベータを投与することを含む呼吸器ウイルスに対する予防的投与方法
TW202315603A (zh) 用於治療登革熱病毒感染之方法
Aoki Peramivir
TW202102224A (zh) 使用經取代之多環吡啶酮衍生物及其前藥於患有流感及嚴重流感病況之個體中治療流感
Alfano et al. Le Infezioni in Medicina, n. 1, 11-21, 2022

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260129